January 7, 2025 - 22:10

As the new year begins, the stock market has not experienced the anticipated Santa Claus rally, but that hasn't deterred equities from showing signs of life in early January. Zachary Hill, Head of Portfolio Strategy at Horizon Investments, describes the concept of a Santa Claus rally as merely "a statistical anomaly." Instead, he is focusing on the upcoming earnings season as a significant catalyst for market movements in 2025.
Hill emphasizes the importance of monitoring not only the fourth-quarter earnings but also the full-year guidance for 2025. He notes a shift in market sentiment regarding the Federal Reserve's approach to growth and inflation. Currently, the S&P and small-cap stocks have seen a decline from their positions before the Fed's interest rate cuts in December.
Crucially, Hill points out that the Fed is still considering further interest rate cuts rather than increases, which will influence market dynamics. Additionally, he highlights the volatility surrounding President-elect Donald Trump's proposed tariff policies as another critical uncertainty for the year ahead.
Both interest rates and trade policies are poised to be significant factors that investors will closely monitor as 2025 unfolds.
February 11, 2026 - 22:18
Credit card debt hits record $1.28 trillion. Here's why — and how to get ahead of it.American households are shouldering a record-breaking burden of credit card debt, with total balances reaching a staggering $1.28 trillion. This new peak signals growing financial strain as...
February 11, 2026 - 03:38
The Rise of Separate Finances: Couples Rethink Joint AccountsA significant shift is underway in how couples manage their money. Recent trends show that fewer than two in five American couples now opt to completely merge their finances in a joint bank account...
February 10, 2026 - 03:34
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor ConferencesPraxis Precision Medicines, Inc., a leader in central nervous system precision neuroscience, has scheduled the release of its fourth quarter and full year 2025 financial results for Thursday,...
February 9, 2026 - 05:04
Best moves for your portfolio: Buy Ulta Beauty, avoid AristaA recent market analysis highlighted a clear divergence in stock recommendations, with a prominent portfolio manager advocating for shares of Ulta Beauty while advising caution on Arista Networks....